AKT1 and lung carcinoma: To determine whether this Akt recovery following gefitinib treatment is a common phenomenon among the lung cancer cell lines, we also evaluated Akt activation in two additional NSCLC cell lines, NCI-H2023 and NCI-H2126, both of which are derived from adenocarcinoma lung cancer.